In a letter to U.S. trade representatives, the AHA challenged the Biden administration’s proposal to increase tariff rates on syringes, needles, personal protective equipment, and medical and surgical gloves. The administration said the plan will confront China’s unfair trade practices and incentivize domestic medical supply manufacturing.
The AHA disagrees, arguing “this strategy may fail or bring negative unintended consequences.”
China-based manufacturers dominate the market for some commonly used medical supplies, and other sources are unlikely to meet domestic demand, the AHA said, so the U.S. healthcare industry might have to continue buying these more expensive products. The organization also said hospitals have existing contracts with China-based manufacturers, and it is burdensome to test and adopt new devices.
Read the letter here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.